FY2024 EPS Estimate for Journey Medical Decreased by Analyst

Journey Medical Co. (NASDAQ:DERM - Free Report) - Roth Capital decreased their FY2024 EPS estimates for shares of Journey Medical in a research note issued to investors on Monday, November 18th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($1.00) for the year, down from their previous estimate of ($0.93). The consensus estimate for Journey Medical's current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Journey Medical's Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.09 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

DERM has been the subject of a number of other reports. Rodman & Renshaw assumed coverage on shares of Journey Medical in a report on Thursday, August 22nd. They issued a "buy" rating and a $9.00 price target for the company. Lake Street Capital started coverage on shares of Journey Medical in a research report on Friday, September 6th. They issued a "buy" rating and a $9.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Journey Medical has a consensus rating of "Buy" and an average target price of $9.38.

Journey Medical Trading Down 1.1 %

NASDAQ DERM traded down $0.06 during mid-day trading on Thursday, reaching $5.17. 55,262 shares of the stock were exchanged, compared to its average volume of 120,139. Journey Medical has a one year low of $2.85 and a one year high of $8.11. The stock has a 50 day simple moving average of $5.64 and a 200-day simple moving average of $5.09. The stock has a market cap of $107.17 million, a P/E ratio of -5.56 and a beta of 0.92. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after purchasing an additional 12,882 shares in the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in shares of Journey Medical in the 3rd quarter valued at $66,000. Nwam LLC purchased a new stake in shares of Journey Medical in the 3rd quarter valued at $59,000. ORG Wealth Partners LLC bought a new stake in Journey Medical during the 3rd quarter valued at $110,000. Finally, PVG Asset Management Corp bought a new stake in Journey Medical during the 2nd quarter valued at $894,000. Hedge funds and other institutional investors own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.